Table 1.
Demographic and clinical characteristics of six groups of individuals
| MCI (n=189) | AD (n=330) | VCI (n=57) | FTD (n=47) | DLB (n=21) | HC (n=246) | |
|---|---|---|---|---|---|---|
| Age (years) | 64.77 ± 9.30 | 64.60 ± 9.75 | 67.18 ± 9.80 | 61.36 ± 8.69 | 72.01 ± 9.07 | 63.85 ± 8.20 |
| Sex (male, %) | 68, 35.98 | 121, 36.67 | 31, 54.39 | 23, 48.94 | 13, 61.90 | 104, 42.28 |
| ADO | 62.78 ± 9.42 | 61.80 ± 9.91 | 61.47 ± 11.06 | 61.74 ± 10.42 | 62.67 ± 10.49 | - |
| COD | 1.98 ± 1.91 | 2.90 ± 2.49 | 1.75 ± 1.97 | 2.79 ± 1.65 | 2.00 ± 2.31 | - |
| MMSE | 22.70 ± 4.48 | 11.63 ± 6.28 | 13.51 ± 6.98 | 12.20 ± 7.41 | 12.76 ± 6.44 | 28.62 ± 1.09 |
| MoCA | 16.22 ± 5.01 | 7.02 ± 4.87 | 7.74 ± 4.86 | 7.68 ± 6.74 | 5.94 ± 5.65 | - |
| Aβ42 (pg/ml) | 587.46 ± 439.59 | 408.29 ± 217.28 | - | - | - | - |
| Aβ40 (pg/ml) | 8572.50 ± 6108.20 | 8286.91 ± 6000.22 | - | - | - | - |
| Aβ42/40 | 0.09 ± 0.07 | 0.06 ± 0.04 | - | - | - | - |
| t-tau (pg/ml) | 316.58 ± 289.84 | 506.21 ± 316.95 | - | - | - | - |
| p-tau (pg/ml) | 76.79 ± 51.92 | 104.39 ± 51.94 | - | - | - | - |
| APOE ε4 (%) | 43.86 (25/57) | 52.00 (78/150) |
Fifty-seven with MCI and 150 with AD, completed APOE genotype testing, 43.86% and 52.00% of whom were APOE ε4 carriers (at least one ε4 allele), respectively. In addition, 28 with MCI and 87 with AD completed the CSF core biomarkers testing
ADO age of disease onset, COD course of disease